Surgical and medical therapy for gastroesofageal reflux disease - Consensus of pro/con clinical debate;Chirurgische und medikamentöse therapie der gastroösophagealen refluxkrankheit - Konsens einer pro- und contra-diskussion

Zeitschrift fur Gastroenterologie

Volumn 41, Issue 8, 2003, Pages 729-732

  Holscher A H ^b   Blum, A L ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ANTIREFLUX OPERATION; BARRETT ESOPHAGUS; EVIDENCE BASED MEDICINE; GASTROESOPHAGEAL REFLUX; HUMAN; PRACTICE GUIDELINE; RESPIRATORY TRACT DISEASE; REVIEW; SYMPTOM; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

ADULT; AGE FACTORS; AGED; BARRETT ESOPHAGUS; ENDOSCOPY; EVIDENCE-BASED MEDICINE; GASTROESOPHAGEAL REFLUX; HERNIA, HIATAL; HUMANS; META-ANALYSIS; PATIENT COMPLIANCE; PROTON PUMPS; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS;

EID: 18544409878     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-41209     Document Type: Review

References (80)

1. Dent J, Brun J, Fendrick AM et al. On behalf of the Genval Workshop Group. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999; 44 (Suppl 2): 1-16
2. Inadomi JM, Jamal R, Murata GH et al. Step-down management of gastroesophageal reflux disease. Gastroenterology 2001; 121 (5): 1095-1100
3. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Phamacol Ther 2001; 15: 1729-1736
4. Thjodleifsson B, Rindi G, Fiocca R et al. A randomized double blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment Pharmacol Ther 2003; 17: 343-351
5. Van der Peet DL, Klinkenberg-Knol EC, Eijsbouts QAJ et al. Laparoscopic Nissen fundoplication for the treatment of gastroesophageal reflux disease (GERD); surgery after extensive conservative treatment. Surg Endosc 1998; 1: 1159-1161
6. Campos GM, Peters JH, DeMeester TR et al. Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication. J Gastrointest Surg 1999; 3 (3): 292-300
7. Kahrilas PJ. Management of GERD: Medical versus surgical. Seminars in Gastrointestinal Disease 2001a; 12: 3-15
8. Kahrilas PJ. Surgical therapy for reflux disease. JAMA 2001b; 2376-2378
9. Galmiche JP, Zerbib F. Antagonist. Laparoscopic fundoplication is the treatment of choice for gastro-oesophageal reflux disease. Gut 2002; 51: 472-474
10. Lundell L. Protagonist. Laparoscopic fundoplication is the treatment of choice for gastro-oesophageal reflux disease. Gut 2002; 51: 468-471
11. Parilla P, de Martinez Haro LF, Ortiz A et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg 2003; 237: 291-298
12. Peghini PG, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects. Gastroenterology 1998; 115 (6): 1335-1339
13. Farrell TM, Richardson WS, Trus TL et al. Response of atypical symptoms of gastro-oesophageal reflux to antireflux surgery. Br J Surg 2001; 88 (12): 1649-1652
14. Amin MR, Postma GN, Johnson P et al. Proton pump inhibitor resistance in the treatment of laryngopharygeal reflux. Otolaryngol Head Neck Surg 2001; 125: 374-378
15. Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm 1999; 56 (23, Suppl 4): S11-17
16. Gerson LB, Hatton BN, Ryono R et al. Clinical and fiscal impact of lansoprazole intolerance in veterans with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 4 (4): 397-406
17. Cordes A, Vogt W, Maier KP. Pantozol-induzierte Hepatitis. Dtsch Med Wochenschr 2003; 128: 611-614
18. Hungin AP, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999; 49 (443): 463-464
19. Dent J. Controversies in long-term management of reflux disease. Baillère's Clinical Gastroenterology 2000; 14: 811-826
20. Romagnuolo J, Meier MA, Sadowski DC. Medical or surgical therapy for erosive reflux esophagitis: cost utility analysis using a Markov model. Ann Surg 2002; 236 (2): 191-202
21. O'Boyle CJ, Watson DI, DeBeaux AC et al. Preoperative prediction of long-term outcome following laparoscopic fundoplication. ANZ J Surg 2002; 2: 471-475
22. Granderath FA, Kamolz T, Schweiger UM et al. Outcome after laparoscopic antireflux surgery: fundoplication and re-fundoplication in the elderly. Chirurg 2001; 72 (9): 1026-1031
23. Klinkenberg-Knol EC, Festen HP, Jansen JB et al. Long term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121 (3): 161-167
24. Klinkenberg-Knol EC, Nelis F, Dent J et al. Long term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118 (4): 661-669
25. Peters FT, Ganesh S, Kuipers EJ et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999; 45: 489-494
26. Vela MF, Camacho Lobato L, Srinivasan R et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001; 120 (7): 1599-1606
27. Lundell L, Miettinen P, Myrvold HE et al. Continued (5 year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 2001; 192: 172-181
28. Taha AS, Angerson WJ, Morran CG. Reflux and Barrett's oesophagitis after gastric surgery - long-term follow-up and implications for the roles of gastric acid and bile in oesophagitis. Aliment Pharmacol Ther 2003; 17: 547-552
29. Ortiz A, de Martinez Haro LF, Parrilla P et al. Conservative treatment versus antireflux surgery in Barrett's oesophagus: long term results of a prospective study. Br J Surg 1996; 83 (2): 274-278
30. Spechler SJ, Lee E, Ahnen D et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285: 2331-2338
31. Ye W, Chow WH, Lagergren J et al. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology 2001; 121 (6): 1286-1293
32. Klaus A, Hinder RA. Medical therapy versus antireflux surgery in Barrett's esophagus: what is the best therapeutic approach? Dig Dis 2000-2001; 18: 224-231
33. Gutschow CA, Schröder W, Prenzel K et al. Impact of antireflux surgery on Barrett's esophagus. Langenbecks Arch Surg 2002; 387: 3-4; 138-145
34. P van, Numans ME, Bonis PA et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2001; 4: CD002095
35. Basu KK, Bale R, West KP et al. Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy. Eur J Gastroenterol Hepatol 2002; 14 (11): 1187-1192
36. You JH, Lee AC, Wong SC et al. Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2003; 17: 785-792
37. Leeder PC, Watson DI, Jamieson GG. Laparoscopic fundoplication for patients with symptoms but no objective evidence of gastroesophageal reflux. Dis Esoph 2002; 15 (4): 309-314
38. Maziak DE, Todd TRJ, Pearson FG. Massive hiatus hernia: evaluation and surgical management. J Thorac Cardiovasc Surg 1998; 115: 53-62
39. van Herwaarden MA, Samsom M, Smout AJ. Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. Gastroenterology 2000; 119 (6): 1439-1446
40. Jones MP, Sloan SS, Rabine JC et al. Hiatal hernia size is the dominant determinant of esophagitis presence and severity of gastroesophageal reflux disease. Am J Gastroenterol 2001; 96: 1711-1717
41. Avidan B, Sonnenberg A, Schnell TG et al. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002; 97 (8): 1930-1936
42. Stylopoulos N, Gazelle GS, Rattner DW. Paraesophageal hernias: operation or observation. Ann Surg 2002; 236: 492-501
43. Kleinmann E, Halbfass HJ. Zur Problematik des "short esophagus" in der laparoskopischen Antirefluxchirurgie. Chirurg 2001; 72: 408-413
44. Streets CG, DeMeester SR, DeMeester TR et al. Excellent quality of life after Nissen fundoplication depends on successful elimination of reflux symptoms and not the invasiveness of the surgical approach. Ann Thorac Surg 2002; 74 (4): 1019-1024; discussion 1024-1025
45. Deschamps C, Allen MS, Trastek VF et al. Early experience and learning curve associated with laparoscopic Nissen fundoplication. J Thorac Cardiovasc Surg 1998; 115: 281-284
46. Rantanen TK, Halme TV, Luostarinen ME et al. The long term results of open antireflux surgery in a community-based health care center. Am J Gastroenterol 1999; 94: 1777-1781
47. Rydberg L, Ruth M, Abrahamsson H et al. Tailoring antireflux surgery: A randomized clinical trial. World J Surg 1999; 23: 612-618
48. Csendes A, Burdiles P, Korn O et al. Late results of a randomized clinical trial comparing total fundoplication versus calibration of the cardia with posterior gastropexy. Br J Surg 2000; 87 (3): 289-297
49. Bais JE, Bartelsman JF, Bonjer HJ et al. Laparoscopic or conventional Nissen fundoplication for gastro-oesophageal reflux disease: randomised clinical trial. The Netherlands Antireflux Surgery Study Group. Lancet 2000; 355: 170-174
50. Hagedorn C, Lonroth H, Rydberg L et al. Long-term efficacy of total (Nissen-Rossetti) and posterior partial (Toupet) fundoplication. Results of a randomized clinical trial. J Gastrointest Surg 2002; 31 (6) (4): 540-545
51. Hüttl TP, Hohle M, Meyer G et al. Antireflux surgery in Germany. Results of a representative survey with analysis 2,540 antireflux operations. Chirurg 2002; 73 (5): 451-461
52. Vakil N, Shaw M, Kirby R. Clinical effectiveness of laparoscopic fundoplication in a U.S. community. Am J Med 2003; 1114: 1-5
53. Tan LC, Samanta S, Hosking SW. Safe transition from open to laparascopic fundoplication by an established consultant - the importance of repeated audit. Ann R Coll Surg Engl 2002; 84: 84-88
54. Menon VS, Manson JM, Baxter JN. Laparascopic fundoplication: learning curve and patient satisfaction. Ann R Coll Surg Engl 2003; 85: 10-13
55. Fibbe C, Layer P, Keller J et al. Esophageal motility in reflux disease before and after fundoplication: A prospective, randomized, clinical, and manometric study. Gastroenterology 2001; 121 (1): 5-14
56. Avidan B, Sonnenberg A, Schnell TG et al. There are no reliable symptoms for erosive oesophagitis and Barrett's oesophagus: endoscopic diagnosis is still essential. Aliment Pharmacol Ther 2002; 16: 735-742
57. Khajanchee YS, O'Rourke RW, Lockhart B et al. Postoperative symptoms and failure after antireflux surgery. Arch Surg 2002; 137: 1008-1013
58. Blom D, Peters JH, DeMeester TR et al. Physiologic mechanism and preoperative prediction of new-onset dysphagia after laparoscopic Nissen fundoplication. J Gastrointest Surg 2002; 6: (1): 22-27; discussion 27-28
59. Booth M, Stratford J, Dehn TC. Preoperative esophageal body motility does not influence the outcome of laparoscopic Nissen fundoplication for gastroesophageal reflux disease. Dis Esophagus 2002; 15 (1): 57-60
60. Martinez SD, Malagon IB, Garewal HS et al. Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Phamacol Ther 2003; 17: 537-545
61. Van der Burgh A, Dees J, Hop WC et al. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. GUT 1996; 39: 5-8
62. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998; 93 (7): 1028-1032
63. MacDonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus. Observational study. Br Med J 2000; 321: 1252-1255
64. Sontag SJ. Preventing death of Barrett's cancer: does frequent surveillance endoscopy do it? Am J Med 2001; 3 (111 Suppl 8A): 137S-141
65. Corley DA, Levin TR, Habel LA et al. Surveillance and survival in Barrett's adenocarcinoma; a population-based study. Gastroenterology 2002; 122: 633-640
66. Parrilla P, de Martinez Haro LF, Ortiz A et al. Standard antireflux operations in patients who have Barrett's esophagus. Current results. Chest Surg Clin N Am 2002; 12: 113-126
67. Carlson MA, Frantzides CT. Complications and results of primary minimally invasive antireflux procedures: a review of 10,735 reported cases. J Am Coll Surg 2001; 193 (4): 428-439
68. Schäfer H, Collet P, Wolfgarten E et al. Endoskopische Gastroplastik zur Behandlung der gastroösophagealen Refluxerkrankung - eine Pilotstudie. Visceralchirurgie 2001; 36: 362-366
69. Devière J, Pastorelli A, Louis H et al. Endoscopic implantation of a biopolymer in the lower esophageal sphincter for gastroesophageal reflux: a pilot study. Gastrointest Endosc 2002; 55 (3): 335-341
70. Triadafilopoulos G, DiBaise JK, Nostrant TT et al. The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the U.S. open label trial. Gastrointest Endosc 2002; 55 (2): 149-156
71. Wolfsen HC, Richards WO. The Stretta procedure for the treatment of GERD: a registry of 558 patients. J Laparoendosc Adv Surg Tech 2002; 12: 395-402
72. Mahmood Z, McMahon BP, Arfin Q et al. Endocinch therapy for gastro-oesophageal reflux disease: a one year prospective follow up. Gut 2003; 52 (1): 34-39
73. Peters JH, Silverman DE, Stein A. Lower esophageal sphincter injection of a biocompatible polymer. Surg Endosc 2003; 17 (4): 547-550
74. Heudebert GR, Marks R, Wilcox M et al. Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis. Gastroenterology 1997; 112: 1078-1086
75. Myrvold HE, Lundell L, Miettinen P et al and the Nordic GORD Study Group. The cost of long term therapy for gastro-oesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery. Gut 2001; 49 (4): 488-494
76. O'Connor JB, Provenzale D, Brazer S. Economic considerations in the treatment of gastroesophageal reflux disease: a review. Am J Gastroenterol 2000; 95 (12): 3356-3364
77. Sonnenberg A. Motion - laparoscopic Nissen fundoplication is more cost effective than oral PPI administration: arguments against the motion. Can J Gastroenterol 2002; 16: 627-631
78. Swanström LL. Motion - laparoscopic Nissen fundoplication is more cost effective than oral PPI administration: arguments for the motion. Can J Gastroenterol 2002; 16: 621-623
79. Hadorn DC, Baker D. Development of the AHCPR-sponsored heart failure guideline: methodologic and procedural issues. Jt Comm J Qual Improv 1994; 20: 539-547
80. Bollschweiler E. Nationale und klinikinterne Leitlinien: Definition und Problemlage. In: Lauterbach KW, Schrappe M (Hrsg). Gesundheitsökonomie, Qualitätsmanagement und Evidence-based Medicine. Stuttgart: Schattauer-Verlag 2001; 457-462